Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 1/2 5

Status

Terminated 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Carcinoma, Non-Small-Cell Lung 91Melanoma 74Squamous Cell Carcinoma of Head and Neck 47Neoplasms 44Neoplasm Metastasis 43Lung Neoplasms 37Carcinoma, Renal Cell 36Colorectal Neoplasms 35Breast Neoplasms 34Triple Negative Breast Neoplasms 30Stomach Neoplasms 26Carcinoma, Transitional Cell 26Ovarian Neoplasms 25Head and Neck Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 21Esophageal Neoplasms 20Pancreatic Neoplasms 18Uterine Cervical Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 16Small Cell Lung Carcinoma 15Carcinoma, Hepatocellular 15Sarcoma 13Recurrence 12Glioblastoma 12Carcinoma 12Prostatic Neoplasms 11Lymphoma 11Mesothelioma 9Carcinoma, Merkel Cell 9

Interventions

Injections 7pembrolizumab 5Paclitaxel 5Bevacizumab 5Leucovorin 4Fluorouracil 4Carboplatin 4trifluridine tipiracil drug combination 3Pemetrexed 3Oxaliplatin 3Irinotecan 3Docetaxel 3Capecitabine 3toripalimab 2tislelizumab 2fludarabine 2Nivolumab 2Gemcitabine 2Fulvestrant 2Cisplatin 2BMS-753493 2130-nm albumin-bound paclitaxel 2urelumab 1ulixertinib 1palbociclib 1mogamulizumab 1lenvatinib 1fluzoparib 1duvelisib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumors × pembrolizumab × Clear all
NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Active not recruiting
226 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06795412 2026-05-04

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Pyxis Oncology, Inc

Phase 1/2 Recruiting
220 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05394350 2024-11-08

MK-1088-002

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
27 enrolled 19 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02880371 2022-06-16

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Pfizer

Phase 1/2 Terminated
82 enrolled 32 charts
Other solid neoplasm

Advanced Solid Tumors

NCT04699643 2021-01-07

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

EverNov Medicines (Zhuhai Hengqin) Co., Ltd

Phase 1/2 Unknown
80 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡